Results from ArriVent BioPharma’s FURMO-002 Phase 1b trial of firmonertinib have reached Cancer Cell, a peer-reviewed journal whose editorial bar tends to filter out early-stage data that hasn’t shown something genuinely unexpected. The fact that this publication happened at all is worth attention: firmonertinib targets EGFR PACC mutations, a structurally distinct subgroup that causes the kinase domain to compress in a way that blunts standard EGFR inhibitors, and front-line data in that population has been scarce.

The PACC mutation angle matters clinically because patients harboring these alterations have historically been difficult to place on approved regimens designed for exon 19 deletions or L858R mutations. Osimertinib, now approved in combination with platinum chemotherapy for those canonical mutations, does not address the PACC subgroup with the same selectivity. Firmonertinib was built to be both mutant-selective and brain-penetrant, a combination that matters in NSCLC given how frequently the disease spreads to the central nervous system.

FURMO-002 ran as a two-stage open-label study, starting with dose escalation to establish safety and then expanding into specific patient cohorts. The 8-K discloses the publication but not the headline efficacy numbers; those live in the Cancer Cell paper itself. What the regulatory filing does confirm is that ArriVent treated the data as material enough to report under Regulation FD, which means the company views the publication as potentially market-moving information for investors, not routine housekeeping.

For trial watchers, the concrete next signal is whether ArriVent uses this Phase 1b dataset to justify a registrational design, and specifically how they scope the PACC-mutant population for enrollment. Phase 1b results published in a high-impact journal with front-line data in hand typically precede a dose-selection announcement; the absence of that announcement alongside this filing is the open question.

Source link: https://www.sec.gov/Archives/edgar/data/1868279/000110465926116736/tm2627799d1_8k.htm

FURMO-002: the facts in one place

  • Also written: firmonertinib, alflutinib mesylate, AST-2818, furmonertinib mesylate, Ivesa, vometinib mesylate, FURTHER
  • Sponsor: ArriVent BioPharma, Inc. in collaboration with Shanghai Allist Pharmaceuticals
  • Mechanism: oral, mutation-selective EGFR inhibitor targeting classical and uncommon EGFR mutations including PACC and exon 20 insertion mutations
  • Indication studied: advanced EGFR PACC-mutant non-small cell lung cancer (treatment-naive, first-line)
  • Phase: 1b
  • Primary endpoint: confirmed objective response rate (ORR) by blinded independent central review
  • Headline result: 68% ORR and median progression-free survival of 16 months at the 240 mg dose
  • Registry identifier: NCT05364073
  • Current status: Phase 1b results published October 19, 2026; global Phase 3 ALPACCA trial (FURMO-006; NCT07185997) currently enrolling for first-line EGFR PACC-mutant NSCLC; holds FDA Breakthrough Therapy Designation and Orphan Drug Designation
  • FDA Breakthrough Therapy Designation granted: October 31, 2023
  • Phase 3 ALPACCA trial initiated: December 17, 2025
  • Cancer Cell publication: October 19, 2026
  • Phase 3 ALPACCA trial estimated completion: December 1, 2030
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.